Immunitybio Inc (IBRX) Stock Analysis

Immunitybio Inc (IBRX) is a publicly traded company in the HEALTHCARE sector. It trades at $7.23, carries a market capitalization of $7.88B. This page summarizes the public market data, fundamentals, and frequently asked questions for IBRX, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $7.23
• Market Cap: $7.88B
• EPS: $-0.85
• 52-Week High: $12.43
• 52-Week Low: $1.95

Market Sentiment

Immunitybio Inc currently has a Bullish sentiment score of 0.34.

About Immunitybio Inc

ImmunityBio, Inc. is a pioneering immunotherapy company focused on developing innovative treatments utilizing memory T-cells to combat a wide range of cancer types. The company's proprietary cancer vaccine aims to create an effective therapeutic approach that minimizes the reliance on high-dose chemotherapy while enhancing the body's immune response against tumors. By leveraging advanced biotechnology, ImmunityBio strives to transform cancer treatment and improve patient outcomes, positioning...

GNG Research Analysis

GNG Research scores Immunitybio Inc (IBRX) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for IBRX.

Frequently Asked Questions

Does IBRX pay dividends?

Immunitybio Inc (IBRX) does not currently pay a regular dividend.

What is IBRX's market cap?

Immunitybio Inc (IBRX) has a market capitalization of $7.88B with a current stock price of $7.23.